The role of fluoroquinolones (FQs) as empirical therapy for community-acquired pneumonia (CAP) remains controversial in countries with high tuberculosis (TB) endemicity owing to the possibility of delayed TB diagnosis and treatment and the emergence of FQ resistance in Mycobacterium tuberculosis38oC), infection involving the upper lobe, presence of cavitary infiltrates, low total white blood cell count, and the presence of lymphopenia are predictive of pulmonary TB.
展开▼
